Highly active antiretroviral therapy (HAART) has been effective in prolonging and improving the quality of life by significant reduction in morbidity and mortality in HIV/AID patients. HAART and other HIV treatments not only keep people alive longer, they also provide a better quality of life, allowing people to return to work and school, take care of their families, and contribute to their communities.
Numerous studies have shown that the efficacy of HAART in suppression of HIV in Africa is comparable to that obtained in resource-rich countries though there are conflicting data on whether HBV co-infection affects HIV suppression. In the developed world setting, liver disease has emerged as a leading cause of death in the era of HAART and viral hepatitis co-infection plays an important role in the progression to cirrhosis in hepatitis B and hepatitis C patients, who are co-infected with HIV. This pattern has continued despite increasing availability and administration of HBV-active HAART. (Nimzing G Ladep, Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa).
Journal of AIDS & Clinical Research published by OMICS Group focuses on the HAART and it has many related articles in it archive page. Journal of AIDS & Clinical Research also organizing related conferences integrated with workshops, symposia, trade shows by bringing together people on a single platform thereby achieving its motto of rapidly increasing the flow of information and there by enlightening the lamp of knowledge across the globe on Science, Medicine and Technology.
Last date updated on January, 2021